HIF-1α promotes the migration and invasion of hepatocellular carcinoma cells via the IL-8–NF-κB axis

• Autorzy: Feng W. , Xue T. , Huang S. , Shi Q. , Tang C. , Cui G. , Guo H.
• Języki publikacji: EN

Abstrakty

EN

Background: Hypoxia plays a critical role in many cancers. Hypoxia inducible factor-1α (HIF-1α) is an important mediator of the hypoxia response. It regulates the expression of various chemokines involved in tumor growth, angiogenesis and metastasis but the associated pathway needs further investigation. Methods: The expression level of HIF-1α was determined in hepatocellular carcinoma (HCC) cells. The correlation of interleukin-8 (IL-8) and HIF-1α was assessed by knocking down HIF-1α. These cells were also used to assess its influence on HCC cell migration and invasion was checked. Pyrrolidinedithiocarbamate (PDTC), an inhibitor of NF-κB, was used to confirm the associated signaling pathway. Results: HIF-1α was significantly expressed in HCC cells and found to promote HCC cell migration and invasion in an IL-8-dependent manner. NF-κB was confirmed to be involved in the process. Conclusions: HIF-1α promotes HCC cell migration and invasion by modulating IL-8 via the NF-κB pathway.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2018
• Tom: 23
• Opis fizyczny: p.1-8,fig.,ref.

Twórcy

autor

Feng W.

• Department of Hepatobiliary Pancreatic Surgery, The First People’s Hospital of Huzhou, No. 158 Guangchanghou Road, Huzhou, Zhejiang Province 313000, People’s Republic of China

autor

Xue T.

• Department of Hepatobiliary Pancreatic Surgery, The First People’s Hospital of Huzhou, No. 158 Guangchanghou Road, Huzhou, Zhejiang Province 313000, People’s Republic of China

autor

Huang S.

• Department of Hepatobiliary Pancreatic Surgery, The First People’s Hospital of Huzhou, No. 158 Guangchanghou Road, Huzhou, Zhejiang Province 313000, People’s Republic of China

autor

Shi Q.

• Department of Hepatobiliary Pancreatic Surgery, The First People’s Hospital of Huzhou, No. 158 Guangchanghou Road, Huzhou, Zhejiang Province 313000, People’s Republic of China

autor

Tang C.

• Department of Hepatobiliary Pancreatic Surgery, The First People’s Hospital of Huzhou, No. 158 Guangchanghou Road, Huzhou, Zhejiang Province 313000, People’s Republic of China

autor

Cui G.

• Department of Hepatobiliary Pancreatic Surgery, The First People’s Hospital of Huzhou, No. 158 Guangchanghou Road, Huzhou, Zhejiang Province 313000, People’s Republic of China

autor

Guo H.

• Department of Hepatobiliary Pancreatic Surgery, The First People’s Hospital of Huzhou, No. 158 Guangchanghou Road, Huzhou, Zhejiang Province 313000, People’s Republic of China

Bibliografia

• 1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–43.
• 2. El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007;132(7):2557–76.
• 3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–17.
• 4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55.
• 5. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229–35.
• 6. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors (HIFs): master regulators of metastasis. Clin Cancer Res. 2010; 16(24):5928–35.
• 7. Lee JH, Hur W, Hong SW, Kim J, Kim SM, Lee EB, Yoon SK. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α. Oncol Rep. 2017;37(2):813–22.
• 8. Zhang L, Huang G, Li X, Zhang Y, Jiang Y, Shen J, et al. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC Cancer. 2013;13:108.
• 9. Liu Y, Zhang J-B, Qin Y, Wang W, Wei L, Teng Y, et al. PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability. Hepatology. 2013;58(2):692–705.
• 10. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510–4.
• 11. Semenza GL, Jiang B-H, Leung SW, Passantino R, Concordet J-P, Maire P, et al. Hypoxia response elements in the aldolase a, enolase 1, and lactate dehydrogenase a gene promoters contain essential binding sites for hypoxiainducible factor 1. J Biol Chem. 1996;271(51):32529–37.
• 12. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447–54.
• 13. Dong ZZ, Yao M, Wang L, Wu W, Gu X, Yao DF. Hypoxia-inducible factor-1alpha: molecular-targeted therapy for hepatocellular carcinoma. Mini-Rev Med Chem. 2013;13(9):1295–304.
• 14. Musumeci G, Castorina A, Magro G, Cardile V, Castorina S, Ribatti D. Enhanced expression of CD31/platelet endothelial cell adhesion molecule 1 (PECAM1) correlates with hypoxia inducible factor-1 alpha (HIF-1α) in human glioblastoma multiforme. Exp Cell Res. 2015;339(2):407–16.
• 15. Singh D, Arora R, Kaur P, Singh B, Mannan R, Arora S. Overexpression of hypoxia-inducible factor and metabolic pathways: possible targets of cancer. Cell Biosci. 2017;7:62.
• 16. Majmundar AJ, Wong WJ, Simon MC. Hypoxia inducible factors and the response to hypoxic stress. Mol Cell. 2010; 40(2):294–309.
• 17. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464.
• 18. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001;13(2):167–71.
• 19. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 2001;11(3):293–9.
• 20. Yang M-H, Wu K-J. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle. 2008;7(14):2090–6.
• 21. Mojsilovic-Petrovic J, Callaghan D, Cui H, Dean C, Stanimirovic DB, Zhang W. Hypoxia-inducible factor-1 (HIF-1) is involved in the regulation of hypoxia-stimulated expression of monocyte chemoattractant protein-1 (MCP-1/ CCL2) and MCP-5 (Ccl12) in astrocytes. J Neuroinflammation. 2007;4:12.
• 22. Baay-Guzman GJ, Bebenek IG, Zeidler M, Hernandez-Pando R, Vega MI, Garcia-Zepeda EA, et al. HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation. Respir Res. 2012;13(1):60.
• 23. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007;98(11):1652–8.
• 24. Li X-P, Yang X-Y, Biskup E, Zhou J, Li H-L, Wu Y-F, et al. Co-expression of CXCL8 and HIF-1α is associated with metastasis and poor prognosis in hepatocellular carcinoma. Oncotarget. 2015;6(26):22880–9.
• 25. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19(8):5785–99.
• 26. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-κB function in growth control: regulation of cyclin D1 expression and G(0)/G(1)-to-S-phase transition. Mol Cell Biol. 1999;19(4):2690–8.
• 27. Hinz M, Löser P, Mathas S, Krappmann D, Dörken B, Scheidereit C. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/reed-Sternberg cells. Blood. 2001;97(9):2798.
• 28. Geng R, Tan X, Wu J, Pan Z, Yi M, Shi W, et al. RNF183 promotes proliferation and metastasis of colorectal cancer cells via activation of NF-kappaB-IL-8 axis. Cell Death Dis. 2017;8(8):e2994.
• 29. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.
• 30. Harris AL. Hypoxia — a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.
• 31. Gordan JD, Simon MC. Hypoxia inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev. 2007;17(1):71–7.
• 32. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–32.
• 33. Marc AV, Eelke HG, Arjan JG, Elsken van der W, Paul JD. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med. 2008;8(1):60–7.
• 34. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005; 2005(306):re12.
• 35. Tam BYY, Wei K, Rudge JS, Hoffman J, Holash J, Park S-K, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med. 2006;12(7):793–800.
• 36. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology. 2005;7(2):122–33.
• 37. Yoshimura T, Matsushima K, Oppenheim JJ, Leonard EJ. Pillars article: neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J Immunol. 1987;139:788–93. The Journal of Immunology. 2005;175(9):5569
• 38. Ren Y, Poon RT-P, Tsui H-T, Chen W-H, Li Z, Lau C, et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma. Clin Cancer Res. 2003;9(16):5996.
• 39. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol. 2001;18(2):257–64.

Identyfikatory

DOI

10.1186/s11658-018-0077-1